Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system
- PMID: 15224658
- DOI: 10.1080/07853890410031948
Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system
Abstract
Many neurodegenerative disorders such as Alzheimer's disease (AD) Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are characterized by neuronal damage that may be caused by toxic, abnormal, aggregation-prone proteins. The purpose of this review is threefold: 1) to provide the reader with an overview of the genes involved in the abnormal processing and accumulation of misfolded proteins in neurodegenerative diseases using PD as a model disease; 2) to understand the cellular mechanisms for disposal of abnormal proteins, and the effects of toxic protein accumulation on ubiquitin proteasome system (UPS) and neuronal survival and 3) to discuss the development and challenges of cell culture and animal models for a rational and effective treatment for these disorders.
Similar articles
-
Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.Neuromolecular Med. 2003;4(1-2):95-108. doi: 10.1385/NMM:4:1-2:95. Neuromolecular Med. 2003. PMID: 14528055 Review.
-
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.Neuron. 2003 Oct 9;40(2):427-46. doi: 10.1016/s0896-6273(03)00606-8. Neuron. 2003. PMID: 14556719 Review.
-
Monitoring the ubiquitin/proteasome system in conformational diseases.Ageing Res Rev. 2003 Oct;2(4):433-49. doi: 10.1016/s1568-1637(03)00031-x. Ageing Res Rev. 2003. PMID: 14522245 Review.
-
The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.Trends Neurosci. 2001 Nov;24(11 Suppl):S7-14. doi: 10.1016/s0166-2236(00)01998-6. Trends Neurosci. 2001. PMID: 11881748 Review.
-
Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.Exp Mol Med. 2015 Mar 13;47(3):e147. doi: 10.1038/emm.2014.117. Exp Mol Med. 2015. PMID: 25766616 Free PMC article. Review.
Cited by
-
Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction.Int J Environ Res Public Health. 2011 Dec;8(12):4702-13. doi: 10.3390/ijerph8124702. Epub 2011 Dec 16. Int J Environ Res Public Health. 2011. PMID: 22408597 Free PMC article. Review.
-
The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson's Disease.Neuromolecular Med. 2023 Sep;25(3):313-329. doi: 10.1007/s12017-023-08738-1. Epub 2023 Feb 5. Neuromolecular Med. 2023. PMID: 36739586 Review.
-
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.Metab Brain Dis. 2008 Jun;23(2):147-54. doi: 10.1007/s11011-008-9082-9. Epub 2008 Apr 19. Metab Brain Dis. 2008. PMID: 18425568
-
Variation in ubiquitin system genes creates substrate-specific effects on proteasomal protein degradation.Elife. 2022 Oct 11;11:e79570. doi: 10.7554/eLife.79570. Elife. 2022. PMID: 36218234 Free PMC article.
-
Genetic ablation of calcium-independent phospholipase A2{gamma} leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction.J Biol Chem. 2009 Dec 18;284(51):35632-44. doi: 10.1074/jbc.M109.055194. J Biol Chem. 2009. PMID: 19840936 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous